Olympus Corporation

Management did not provide a full revenue or EPS print in the excerpted Q&A, but it did say the constant-currency revenue guidance was revised down by 2% and that U.S. Q3 performance disappointed. Izumi Tatsuya said the restructuring provision increased to JPY 31 billion, with about 90% booked this fiscal year and 10% next fiscal year, while the JPY 24 billion reduction effect outlook was unchanged. On the ship hold, Izumi said the fourth-quarter revenue impact would be about JPY 18 billion, while related disposal/inventory costs end in Q3. Robert White said the company is not changing its midterm target of 100-plus basis points of annual margin expansion beginning in FY27, and reiterated a long-term goal of mid-single-digit revenue growth and a 20%+ operating margin, while also saying the range-based guidance does not assume additional ship holds.

Robert White framed the quarter as a mix of execution problems and temporary operational disruptions, not a market-share or technology problem. He repeatedly emphasized that Olympus is acting proactively on quality, FDA observations, and product holds, and that the company is tightening oversight and KPIs to improve execution. His tone was defensive but confident, especially around the idea that the company can fix the issues and still return to its midterm growth and margin plan.

Izumi Tatsuya said the restructuring-related cost provision was revised up to JPY 31 billion from JPY 12 billion because costs were recognized earlier through accounting treatment, not because the overall program got bigger. He said roughly 90% of that cost is expected in the current fiscal year and 10% next fiscal year, while the JPY 24 billion effect remains unchanged. On the ship hold, he said the revenue hit in Q4 will be about JPY 18 billion and that disposal-related costs end in Q3; he also said the guidance range helps reflect timing variability as products are released back into market. Robert White added that the company expects to absorb most of the FDA/quality-related costs within SG&A and still deliver more than 100 basis points of annual profit improvement over time.

Analysts pressed on why revenue guidance was cut despite the company’s stated discipline, especially in the U.S. and China. Management answered that the U.S. issue was mainly commercial execution and pipeline conversion, while China is improving gradually after strategy changes such as local manufacturing, dedicated resources, training, and better government relations; they said China growth turned to about 5% after prior double-digit declines. On FDA inspections, management said observations came from 8 facilities, some predated Elevate, and the matter remains open while the company works with the FDA and continues remediation. They also clarified that the company’s new guidance range does not assume additional ship holds, but reflects timing uncertainty as affected products are reintroduced.